CN103327974A - 用于治疗糖尿病和血脂异常的方法和组合物 - Google Patents

用于治疗糖尿病和血脂异常的方法和组合物 Download PDF

Info

Publication number
CN103327974A
CN103327974A CN2011800558120A CN201180055812A CN103327974A CN 103327974 A CN103327974 A CN 103327974A CN 2011800558120 A CN2011800558120 A CN 2011800558120A CN 201180055812 A CN201180055812 A CN 201180055812A CN 103327974 A CN103327974 A CN 103327974A
Authority
CN
China
Prior art keywords
alkyl
cycloalkyl
independently selected
hydrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800558120A
Other languages
English (en)
Chinese (zh)
Inventor
I.罕纳
S.皮拉里塞蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kareus Therapeutics SA
Original Assignee
Kareus Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kareus Therapeutics SA filed Critical Kareus Therapeutics SA
Publication of CN103327974A publication Critical patent/CN103327974A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/27—Polyhydroxylic alcohols containing saturated rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/04—Saturated ethers
    • C07C43/115—Saturated ethers containing carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/12—Saturated polycyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/15—Saturated compounds containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/608—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a ring other than a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2011800558120A 2010-09-20 2011-09-20 用于治疗糖尿病和血脂异常的方法和组合物 Pending CN103327974A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38444610P 2010-09-20 2010-09-20
US61/384,446 2010-09-20
PCT/US2011/052318 WO2012040177A1 (en) 2010-09-20 2011-09-20 Methods and compositions for treatment of diabetes and dyslipidemia

Publications (1)

Publication Number Publication Date
CN103327974A true CN103327974A (zh) 2013-09-25

Family

ID=45818296

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800558120A Pending CN103327974A (zh) 2010-09-20 2011-09-20 用于治疗糖尿病和血脂异常的方法和组合物

Country Status (13)

Country Link
US (2) US8623897B2 (enExample)
EP (1) EP2618824A4 (enExample)
JP (1) JP2013537240A (enExample)
KR (1) KR20140009125A (enExample)
CN (1) CN103327974A (enExample)
AU (1) AU2011305610A1 (enExample)
BR (1) BR112013008675A2 (enExample)
CA (1) CA2812109A1 (enExample)
MX (1) MX2013003078A (enExample)
RU (1) RU2013118021A (enExample)
SG (1) SG188996A1 (enExample)
WO (1) WO2012040177A1 (enExample)
ZA (1) ZA201301936B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623897B2 (en) * 2010-09-20 2014-01-07 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
US20140121267A1 (en) * 2011-09-20 2014-05-01 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia
US9975869B2 (en) * 2013-04-04 2018-05-22 Sphaera Pharma Pvt. Ltd. Analogues of epicatechin and related polyphenols
WO2015002818A1 (en) 2013-07-01 2015-01-08 Emory University Treating or preventing nephrogenic diabetes insipidus
WO2015143276A1 (en) * 2014-03-20 2015-09-24 Esperion Therapeutics, Inc. Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
WO2016149191A1 (en) 2015-03-13 2016-09-22 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107118098B (zh) * 2016-02-25 2020-07-14 中国科学院上海药物研究所 一类脂肪酸类化合物、其制备方法及其用途
CA3071385A1 (en) * 2017-01-31 2018-08-09 Emory University Substituted cycloalkanes for managing nephrogenic diabetes insipidus

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3280169A (en) * 1962-09-18 1966-10-18 Union Carbide Corp Sulfo-substituted aromatic dicarboxylic compounds
EP1443046A1 (en) * 2001-10-09 2004-08-04 Kyorin Pharmaceutical Co., Ltd. Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
CN101677982A (zh) * 2007-02-26 2010-03-24 塞多麦克斯有限公司 治疗心血管病症的组合疗法、组合物和方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3853951A (en) * 1971-07-14 1974-12-10 American Cyanamid Co Preparation of 9-oxo-13-trans-prostenoic acid esters by alanate addition to cyclopentenone
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4739113A (en) * 1986-05-30 1988-04-19 Merck & Co., Inc. Bis(cyclopropanecarboxamido)alkadienedioic acids as renal dipeptidase inhibitors
JPS63246351A (ja) * 1987-04-02 1988-10-13 Rikagaku Kenkyusho ポリケト−ル系化合物及びその合成法
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
FR2740135B1 (fr) 1995-10-20 1997-12-19 Roussel Uclaf Nouveaux derives de pyrazoles acides, leur procede de preparation, leur application a titre de medicaments, leur nouvelle utilisation et les compositions pharmaceutiques les renfermant
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JPH10273469A (ja) * 1997-02-03 1998-10-13 Takeda Chem Ind Ltd ２環性キノン誘導体、製造法および剤
DE19837620A1 (de) 1997-08-22 1999-02-25 Novartis Ag Organische Verbindungen
BRPI9909191B8 (pt) 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
NZ506679A (en) 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
US6387897B1 (en) 1998-06-30 2002-05-14 Neuromed Technologies, Inc. Preferentially substituted calcium channel blockers
US6440996B1 (en) 1998-10-07 2002-08-27 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
EP1130469A1 (en) 2000-02-22 2001-09-05 Lucent Technologies Inc. A radiation-sensitive resist material and a process for device fabrication using the same
DE10010430A1 (de) 2000-03-03 2001-09-06 Bayer Ag Substituierte 5-Ethyl-dihydropyridazinone und ihre Verwendung
CN1962596A (zh) 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
US6544305B2 (en) 2001-04-02 2003-04-08 Ciba Specialty Chemicals Corporation Candle wax stabilized with piperazinones
US6544304B2 (en) 2001-04-02 2003-04-08 Ciba Specialty Chemicals Corporation Candle wax stabilized with morpholinones
US6540795B2 (en) 2001-04-02 2003-04-01 Ciba Specialty Chemicals Corporation Candle wax stabilized with oxazolidines
EP1383832A1 (en) 2001-04-02 2004-01-28 Ciba SC Holding AG Stabilized candle wax
US6547840B2 (en) 2001-04-02 2003-04-15 Ciba Specialty Chemicals Corporation Candle wax stabilized with imidazolidines
US6562084B2 (en) 2001-04-02 2003-05-13 Ciba Specialty Chemicals Corporation Candle wax stabilized with piperazindiones
US6905525B2 (en) 2001-04-02 2005-06-14 Ciba Specialty Chemicals Corporation Candle wax stabilized with piperazinones
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
PT2404890T (pt) 2003-01-23 2017-10-23 Esperion Therapeutics Inc Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
AU2003300438A1 (en) 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
JP2007525408A (ja) * 2003-12-24 2007-09-06 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連使用のためのケトン化合物および組成物
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP5345293B2 (ja) 2007-03-29 2013-11-20 株式会社Ａｄｅｋａ 重合性化合物及び重合性組成物
KR101506055B1 (ko) 2007-09-25 2015-03-25 메르크 파텐트 게엠베하 메소젠 이량체
US8623897B2 (en) * 2010-09-20 2014-01-07 Kareus Therapeutics, Sa Methods and compositions for treatment of diabetes and dyslipidemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3280169A (en) * 1962-09-18 1966-10-18 Union Carbide Corp Sulfo-substituted aromatic dicarboxylic compounds
EP1443046A1 (en) * 2001-10-09 2004-08-04 Kyorin Pharmaceutical Co., Ltd. Novel 4-(2furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
CN101677982A (zh) * 2007-02-26 2010-03-24 塞多麦克斯有限公司 治疗心血管病症的组合疗法、组合物和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GREGORY T. VENTURA ET AL.: ""Analysis of unresolved complex mixtures of hydrocarbons extracted from Late Archean sediments by comprehensive two-dimensional gas chromatography (GC×GC)"", 《ORGANIC GEOCHEMISTRY》, vol. 39, 26 March 2008 (2008-03-26), pages 846 - 867 *
ROEL P. L. BELL ET AL.: "a-Cycloalkyl-substituted x-keto-dicarboxylic acids as lipid regulating agents", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 13, 31 December 2005 (2005-12-31), pages 223 - 236 *
SHINGO OGATA ET AL.: "The first example of regiospecific magnesium carbenoid 1,3-CH insertion: its mechanism and stereochemistry", 《TETRAHEDRON LETTERS》, vol. 48, 31 December 2007 (2007-12-31), pages 5017 - 5021, XP022121354, DOI: doi:10.1016/j.tetlet.2007.05.101 *

Also Published As

Publication number Publication date
WO2012040177A1 (en) 2012-03-29
KR20140009125A (ko) 2014-01-22
ZA201301936B (en) 2014-05-28
SG188996A1 (en) 2013-05-31
RU2013118021A (ru) 2014-10-27
EP2618824A1 (en) 2013-07-31
BR112013008675A2 (pt) 2016-06-21
US8623897B2 (en) 2014-01-07
EP2618824A4 (en) 2015-05-06
MX2013003078A (es) 2013-09-26
JP2013537240A (ja) 2013-09-30
AU2011305610A1 (en) 2013-03-14
CA2812109A1 (en) 2012-03-29
US20140142178A1 (en) 2014-05-22
US20120071528A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
CN103327974A (zh) 用于治疗糖尿病和血脂异常的方法和组合物
TWI322805B (enExample)
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
KR20110069860A (ko) 트라마돌 및 ＮＳＡＩＤｓ의 공결정
JP2008546719A (ja) 結晶形のｏ−デスメチルベンラファキシン
JP4278652B2 (ja) 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
JPWO2000043016A1 (ja) ジカルバ−クロゾ−ドデカボラン誘導体
TW202012380A (zh) 唑化合物晶體
LU85999A1 (fr) Nouvelles isoindolinylalcoylpiperazines
CA2701638A1 (en) Pharmaceutical calcimimetics
JP6275644B2 (ja) Ｎ−［２−（｛２−［（２Ｓ）−２−シアノピロリジン−１−イル］−２−オキソエチル｝アミノ）−２−メチルプロピル］−２−メチルピラゾロ［１，５−ａ］ピリミジン−６−カルボキサミドの結晶
US20140121267A1 (en) Methods and compositions for treatment of diabetes and dyslipidemia
JP5122297B2 (ja) Ｎ−置換サリチルアミドの製造法
TW200524609A (en) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
WO2015137407A1 (ja) ヘテロアリールカルボン酸エステル誘導体の製造方法、その製造中間体及び結晶
US2746901A (en) Glycinamide salts
TW200536816A (en) Crystalline pyrazoles
JP2014189542A (ja) アミド誘導体の製造方法
JPH0395143A (ja) アミノケトン誘導体
JPH04112848A (ja) 結晶性バルプロン酸マグネシウムの製造方法
KR100632470B1 (ko) 결정성 시부트라민 캄실레이트염과 이의 제조방법
KR100806673B1 (ko) 결정상 시부트라민 프리베이스의 제조방법
US20250346567A1 (en) Substituted pyridine and phenyl compounds
JP4840948B2 (ja) フェニル基含有シクロヘキシルアミン誘導体及び中枢神経障害を伴う疾患の治療薬
WO2025221780A1 (en) Salts of irak4 degrader

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130925